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Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E
angiogenin (ANG) mutation
Aims: Five to 10% of cases of amyotrophic lateral sclerosis
are familial, with the most common genetic causes being
mutations in the C9ORF72, SOD1, TARDBP and FUS
genes. Mutations in the angiogenin gene, ANG, have been
identified in both familial and sporadic patients in several
populationswithin Europe andNorthAmerica.The aim of
this studywas to establish the incidence of ANGmutations
in a large cohort of 517 patients from Northern England
and establish the neuropathology associated with these
cases. Methods: The single exon ANG gene was amplified,
sequenced and analysed for mutations. Pathological
examination of brain, spinal cord and skeletal muscle
included conventional histologyand immunohistochemis-
try.Results:Mutation screening identified a single sporadic
amyotrophic lateral sclerosis casewith a p.K54Emutation,
which is absent from 278 neurologically normal control
samples.The clinical presentationwas of limb onset amyo-
trophic lateral sclerosis,with rapid disease progression and
no evidence of cognitive impairment. Neuropathological
examination established the presence of characteristic
ubiquitinated and TDP-43-positive neuronal and glial
inclusions, but no abnormality in the distribution of ang-
iogenin protein. Discussion: There is only one previous
report describing the neuropathology in a single case with
a p.K17IANGmutationwhich highlighted the presence of
eosinophilic neuronal intranuclear inclusions in the hip-
pocampus. The absence of this feature in the present case
indicates that patients with ANGmutations do not always
have pathological changes distinguishable from those of
sporadic amyotrophic lateral sclerosis.
Keywords: amyotrophic lateral sclerosis, angiogenin, glial inclusions, intranuclear inclusions, neuronal inclusions,
neuropathology
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult onset neu-
rodegenerative disease characterized by degeneration of
motor neurones in the cerebral cortex, brainstem and
spinal cord. It results in progressive muscular weakness,
wasting and paralysis that typically causes death within
3–5 years of onset [1]. Five to 10% of ALS cases are famil-
ial and causative mutations have been identified in several
genes, themost common being C9ORF72, SOD1, TARDBP
and FUS [2–7]. An association between the angiogenin
gene (ANG), located on chromosome 14q11.2, and ALS
was originally demonstrated by Greenway and colleagues.
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They identified that the G allele of the synonymous
rs11701 single nucleotide polymorphism (SNP) was over-
represented in Scottish and Irish ALS cases comparedwith
controls [8]. Subsequent screening of the coding region of
theANG gene in 1629ALS cases identified sevenmissense
mutations in 15 ALS patients, including four familial and
11 sporadic cases [9]. Mutations in ANG have subse-
quently been associated with ALS in nine different popu-
lations [10–18]. To date 20 different mutations have been
identified in ALS patients (Table 1), with ANG mutations
accounting for 1.2–2.6% of familial ALS (FALS) cases and
0.35–0.8% of sporadic ALS (SALS) cases.
Mature ANG is a 14 kDa, 123 amino acid, secreted
protein predominantly produced by the liver. It is a
member of the pancreatic ribonuclease superfamily and
was originally identified as a potent factor stimulating new
blood vessel growth secreted by tumour cells [19]. Exog-
enous ANG binds to a 170 kDa receptor on the surface of
endothelial cells and is transported into the cell by
receptor-mediated endocytosis. Once inside the cell ANG is
rapidly translocated to the nucleus where it accumulates
inside the nucleolus. There it binds to ribosomal DNA and
stimulates ribosomal RNA synthesis, a rate-limiting step
in ribosome biogenesis which is required for active cell
proliferation [20]. Both the ribonuclease activity of ANG
and its translocation to the nucleus are essential for its
angiogenic and cell proliferative activity. ANG also has a
role in the cytoplasm where it has been shown to cleave
transfer RNAs in response to cellular oxidative stress
resulting in an important alternative, eIF2a-independent
pathway of translational inhibition [21]. ANG is widely
expressed throughout the adult human nervous system, is
present inside motor neurones and has been shown to be
directly neuroprotective [10,22].
The aim of this investigation was to screen the coding
region of ANG for mutations in a large cohort of patients
from Northern England. We have identified a single SALS
case with a p.K54E mutation; both the clinical and neu-
ropathological findings of the individual are presented.
Materials & methods
Genetic screening
DNA samples were obtained from blood taken from
patients attending the Motor Neurone Disorders Clinic at
the Royal Hallamshire Hospital in Sheffield, England, and
from the Sheffield Brain Tissue Bank, which contains post
mortem tissue donated by ALS patients between 1989 and
2012. In total, 517 cases were screened, and these com-
prised the following groups of patients: 433 ALS (30
FALS), 36 progressive muscular atrophy, 11 progressive
bulbar palsy, nine primary lateral sclerosis, 10 ALS plus
dementia and 18 atypical ALS. None of these cases were
positive for SOD1, TARDBP or FUS mutations; however,
subsequent screening of this cohort identified 13 FALS
and 16 SALS with expansions in the C9ORF72 gene.
Control DNA samples from 278 healthy age- and sex-
matched individuals were obtained from blood samples
donated by unrelated partners and carers of ALS patients,
and from volunteers donating blood for transfusion at
National Blood Service sessions in Sheffield. All cases
and controls were of White Caucasian ethnicity. Approval
for the use of DNA samples was obtained from the local
research ethics committee and donor consent was
obtained.
Genomic DNA was extracted from whole blood and
fresh frozen central nervous system tissue using the
Nucleon BACC Genomic Extraction Kit and Soft Tissue
DNA Extraction Kit, respectively (Tepnel, UK). The ANG
gene was amplified from genomic DNA by PCR using
standard methods and published primer sequences [9].
PCR products were sequenced using BigDye Terminator
v3.1 (Life Technologies, Paisley, UK) according to manu-
facturer’s instructions. Sequencing products were read on
a 3730 DNA Analyser (Life Technologies) and chromato-
graphs were aligned to the available reference sequence
(NM_001145). Residues were numbered in accordance
with the nomenclature recommended by the Human
Genome Variation Society (http://www.hgvs.org). Con-
trols were screened for the c.232A>G substitution by per-
forming restriction digests of the ANG PCR products with
TaqaI using standard methods. Mutant sequences yield
two products at 287 bp and 263 bp, whereas the wild-
type sequence remains uncut (550 bp).
Pathology
An autopsy was performed with the consent of the next of
kin. Representative blocks of brain, spinal cord and skel-
etal muscle were taken and fixed in formalin. They were
then embedded in paraffin wax, sectioned and stained for
haematoxylin and eosin and luxol fast blue. Immunohis-
tochemistry (IHC) for FUS, TDP-43, p62, CD68, ANG,
a-actinin-2 and a-smooth muscle actin was performed
on 5 mm sections (Table 2). This study used the same
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Table 1. ANG mutations reported in ALS cases to date
Population
Number of ALS
patients (SALS/FALS)
Amino acid
substitutions Reference/comments
Scottish
Irish
Swedish
USA (Boston)
England
398 (364/34)
293 (262/31)
434 (334/100)
360 (277/83)
144 (133/11)
p.Q12L (¥2)
*p.K17I (¥2)
p.K17E (¥2)
p.R31K
p.C39W (¥2)
p.K40I (¥3)
p.I46V (¥3)
[9] *p.K17I also identified in one control
North American 298 (not given) p.P(-4)S
p.K17I
p.S28N
p.P112L
[10]
French 855 SALS p.I46V (¥2)
p.R121H
[17]
German 581 SALS p.F(-13)L
*p.K17I
p.I46V
p.K54E
[16] *p.K17I also found in two controls
Dutch 39 FALS index cases *p.K17I [13] *p.K17I in six affected and one unaffected family member
Italian 737 (605/132) p.M(-24)I
p.F(-13)S
p.P(-4)S
*p.I46V (¥6)
p.V113I (¥2)
p.H114R
[11] *p.I46V also found in four controls
Italian 262 (215/12; 35 unknown) *p.I46V (¥1) [12] *p.I46V also found in two controls
South Italian 163 (155/8) p.M(-24)I [15] *p.I46V also found in five controls
Italian 210 SALS None [14]
French 162 FALS index cases p.K17I (¥2)
p.K54E
p.R121H
[40] p.K17I also carried FUS p.R521C, p.K54E also carried FUS p.R521S
Italian 1 p.R145C [41] Also carried SOD1 p.G93D
Belgian
Dutch
Swedish
310 SALS
980 (941/39)
277 SALS
p.M(-24)I (¥2)
p.F(-13)L
p.F(-13)S
p.G(-10)D
p.P(-4)Q
p.P(-4)S (¥2)
p.Q12L (¥2)
p.K17E (¥2)
p.S28N
p.R31K
p.C39W (¥2)
p.K40I (¥6)
p.K54E
p.T80S
p.F100I
p.P112L
p.V113I (¥3)
p.H114R
p.R121H
[18] *p.K17I and p.I46V were observed in all populations in ALS and
controls at comparable frequencies
*Amino acid changes also found in controls.
ALS, amyotrophic lateral sclerosis; SALS, sporadic ALS; FALS, familial ALS.
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antibody for ANG (MANG-1) as was employed in the exist-
ing neuropathologically characterized case report [23].
Results
Genetic screening
Screening of the entire ANG coding region in the 516
cases identified a single heterozygous c.232A>G change
in one patient with SALS (Figure 1). This change results
in the substitution of lysine for glutamate at residue 54,
p.K54E. This substitution was not detected in 278 neu-
rologically normal controls, screened using the TaqaI
digest (Figure 1). In silico analysis using SIFT [24] pre-
dicted that this mutation adversely affects the protein
function, while I-Mutant 2.0 (folding.uib.es/i-mutant/i-
mutant2.0.html) predicted decreased stability of the
encoded protein. The amino acid change is located
within the second helix of the mature ANG protein
(Figure 2). This patient was negative for SOD1, TARDBP
and FUS mutations, as well as negative for the C9ORF72
expansion.
Clinical findings
The individual in whom the p.K54E mutation was identi-
fied was a Caucasian male who presented at the age of 49
years with a 2-month history of lower limb weakness. He
had initially noticed his right leg giving way and unsteadi-
ness of gait. This had progressed over a few weeks to
include right-sided foot drop. He had no significant prior
medical history and no family history of neurological
disease.
Initial neurological examination revealed no abnor-
malities in the cranial nerve territory. Widespread fas-
ciculations were evident in the muscles of all four limbs.
In the upper limbs tone and power were normal bilater-
ally and the reflexes were pathologically brisk. In the
lower limbs, muscle tone was normal. Wasting of the
right quadriceps muscle was observed and power was
reduced bilaterally in hip flexion and ankle dorsiflexion.
Knee jerks were brisk, ankle jerks were depressed and the
plantar responses were flexor. No abnormalities of sensa-
tion were detected.
Routine laboratory investigations revealed only a
slightly elevated creatine kinase level of 557 IU/l (refer-
ence range 25–190 IU/l). Cerebrospinal fluid (CSF)
protein and cytology were normal. Magnetic resonanceTa
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imaging (MRI) of the brain and spine was normal apart
frommultiple wedge fractures of thoracic and lumbar ver-
tebrae without cord compression. Dual energy X-ray
absorbance (DXA) scanning showed only vertebral osteo-
penia. A computerized tomography (CT) body scan per-
formed did not identify any malignancy but did identify
extensive bilateral pulmonary emboli for which the
patient was prescribed warfarin. Respiratory function
testing was normal at presentation. Neurophysiological
examination revealed normal motor and sensory nerve
conduction. Sensory nerve action potentials (SNAP) from
both sural nerves were reduced. Motor studies in the tibial
and peroneal nerves demonstrated reduced compound
muscle action potentials (CMAP). Electromyography
(EMG) in multiple upper and lower limb muscles revealed
neurogenic changes compatible with anterior horn cell
dysfunction. EMG of the tongue and paraspinal muscles
was normal. A sural nerve biopsy was normal.
The patient’s symptoms progressed rapidly resulting in
severe bilateral lower limb weakness and followed by
progressive weakness in the upper limbs. Repeat neuro-
physiology 6 weeks after the initial studies showed wors-
ening motor axonal loss in all four limbs. He subsequently
presented acutely to hospital with an episode of acute res-
piratory muscle weakness and died 6 days later from res-
piratory failure, 5 months after symptom onset. At this
terminal stage of the disease there was no evidence of
bulbar involvement and no cognitive impairment. The
final clinical diagnosis was limb onset ALS, classified as
probable ALS by the El-Escorial criteria.
Pathology findings
Autopsy examination revealed no significant systemic
pathology outside of the nervous system and the brain
appearedmacroscopically normal. Conventional histology
revealed a marked loss of motor neurones (MN) from the
anterior horns of the spinal cord. Residual MN contained
occasional Bunina bodies (Figure 3i,j). Immunohisto-
chemistry (IHC) for p62 revealed compact and skein-like
neuronal cytoplasmic inclusions in MN throughout
the spinal cord, in anterior horn and Clarke’s column
(Figure 3a,b) as well as in the hypoglossal nucleus of the
medulla. IHC for p62 performed on the hippocampus, cer-
ebellum as well as frontal and temporal neocortex did not
show the ubiquitinated neuronal cytoplasmic inclusions
that are characteristic of MND caused by hexanucleotide
repeat expansions of C9ORF72 (data not shown) [25–28].
Compact neuronal cytoplasmic inclusions were seen in
the motor cortex (Figure 3d). Glial cytoplasmic inclusions
(GCI) were also evident (Figure 3b) in motor regions but
not in themidbrain, neocortex or hippocampus. Neuronal
intranuclear inclusions (NII) were not observed with p62
or conventional stains. IHC for TDP-43 revealed both
normal nuclear labelling and neuronal and glial cytoplas-
mic inclusions of similar morphology and distribution to
a b c
287bp
550bp
263bp
K
5
4
E
220 220
C C C C C CA A A A AT TG G G GR
Figure 1. The p.K54E mutation identified in ANG. The non-synonymous A>G nucleotide substitution at position c.232 gives rise to the
amino acid substitution, p.K54E. Chromatograms are shown for wild-type sequence (a), and the heterozygous c.232A>G case (b). Screening
for this change in control samples was conducted by digestion of the ANG PCR product with TaqaI. Presence of the G allele introduces a TaqaI
digest site, resulting in the production of 287 bp and 263 bp fragments from the 550 bp PCR product (c).
Figure 2. Schematic diagram of the ANG protein and location of
the p.K54E mutation. The protein domains and secondary
structure are derived from information provided on the ANG
protein (P03950) found on the UniProt database.
566 J. Kirby et al.
NAN 2013; 39: 562–571© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
Figure 3. Immunohistochemistry of sporadic amyotrophic lateral sclerosis (SALS) case with p.K54E ANG mutation. Images show p62
(a–d), TDP-43 (e–g), FUS (h), angiogenin (i), H&E (j), CD68 (k) and a2 actinin (l) showing: neuronal (a, b, d, e and g) and glial (c and f)
cytoplasmic inclusions in the spinal cord; neuronal cytoplasmic inclusions in the motor cortex (d and g); normal, predominantly nuclear
labelling of FUS in the spinal cord (h), granular cytoplasmic staining in a motor neurone with the appearance of lipofuscin (i); Bunina
bodies (arrowheads; j); a microglial reaction that is most marked in the lateral descending tract of the spinal cord and least marked in the
dorsal columns (k); normal labelling of Z-disc in skeletal muscle by a2 actinin (l). Scale: a–i and l, bar = 20 mm; j, bar = 20 mm;
k, bar = 1 mm.
p.K54E ANG mutation in sporadic ALS 567
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that seenwith p62 IHC (Figure 3e–g).Therewas concomi-
tant loss of nuclear TDP-43 in cells which contained cyto-
plasmicTDP-43 inclusions. IHC forCD68 in the spinal cord
revealed amicroglial reaction in the grey andwhitematter
(Figure 3k). The dorsal columns were spared and the cor-
ticospinal pathways (crossed and uncrossed) were most
severely affected.This tract degenerationwas not apparent
in conventional myelin stains. IHC for ANG revealed
granular labelling of the neuronal cytoplasm as described
elsewhere [23]. The histological appearances suggest that
this most probably corresponds to staining of lipofuscin
(Figure 3i). This pattern of ANG staining was also seen in
the spinal cord tissue from a neurologically healthy
control, a case of SOD1-related ALS and a case of SALS
(data not shown). Staining was also evident in blood leu-
cocytes and ependymal cells, providingan internal positive
control. IHC fora-smoothmuscle actin labelled the smooth
muscle layerof bloodvessels strongly.Therewasnonuclear
or cytoplasmic labelling of neurones or glia in the p.K54E
ANG case. IHC for FUS showed normal, predominantly
nuclear labellingwithout any neuronal cytoplasmic inclu-
sions (Figure 3h), andbA4amyloidwas negative through-
out motor system, midbrain and hippocampus. IHC for
a-actinin-2 in skeletal muscle showed normal labelling of
Z-discs (figure 3l).
Discussion
Mutation screening of the ANG gene in a large cohort of
ALS patients from Northern England identified a single
mutation in a SALS case: c.232A>G that results in
p.K54E amino acid change. This mutation was not
detected in 278 controls from Northern England. A pre-
vious report identified this mutation in a German SALS
patient, while it was absent from 616 controls [16].
Taking into account all the previous reports, as summa-
rized by van Es, the p.K54E mutation is absent from a
total of 7946 controls [9,11–13,18]. The ANG K54
residue is highly conserved in mammals and substitution
of the lysine by glutamic acid is predicted to alter func-
tion and stability, by replacing the basic residue with an
acidic one.
The clinical findings in our case were of a limb onset,
rapidly progressive, predominantly lower motor neurone
ALS phenotype in a 49-year-old male. In addition, the
patient had reduced sural nerve sensory action potentials.
This compares with the previously reported case with a
p.K54E mutation which was also a male who had limb
onset disease but at the much younger age of 28 years
with a longer survival of 24 months and who also had
frontal lobe dysfunction. There was no evidence of cogni-
tive impairment in the case described in this report. Analy-
sis of allANG-related ALS cases where clinical details were
available revealed that approximately 58% of cases are
limb onset and 42% are bulbar (http://alsod.iop.kcl.ac.uk)
[29].
Neuropathology findings have been reported in only
one ANG-related ALS case previously, carrying a p.K17I
substitution [23,30]. A highlighted feature of this case
was the presence of eosinophilic neuronal intranuclear
inclusions in the pyramidal neurones of the hippocampus
and frontal cortex that were immunoreactive for ubiqui-
tin, p62 and a-smooth muscle actin. These were not
detected in the p.K54E ANG case described in this report.
The characteristic ALS neuropathology of TDP-43- and
ubiquitin-positive neuronal and glial inclusions was
present in both cases, while neither case showed any
abnormalities of immunostaining for ANG. The p.K17I
ANG case also showed marked loss of a-actinin-2 immu-
noreactivity in peroneal muscle which was not detected in
our p.K54E ANG case. It also is interesting to note that in
our current case p62/TDP-43-positive neuronal cytoplas-
mic inclusions were identified in Clarke’s column. Neuro-
nal cytoplasmic inclusions have been demonstrated with
immunohistochemistry for p62 in SALS [31], phosphor-
ylated neurofilament in SOD1-associated FALS [32] and
FUS in FUS-associated FALS cases with basophilic inclu-
sions [33].
While the neuropathological findings in our current
case differ from the previous report, this is not surprising
as findings from other ALS genes do not indicate that each
gene has a unique pathological appearance.This is further
supported by the finding of the p.K17I cases’ characteris-
tic neuronal nuclear alpha-actin inclusions neuropathol-
ogy in cases which do not carry ANGmutations (Ansorge,
pers. comm.). In addition, there is some debate as to
whether p.K17I is pathogenic – this substitution is one of
only two ANG nucleotide changes which have also been
identified in controls from Europe [9,16,18]. A recent
study of 6471 ALS cases and 7668 controls concluded
that these two variants, p.K17I and p.I46V, should be con-
sidered as polymorphisms, rather than pathogenic muta-
tions [18].
The discovery of TDP-43 as the signature disease
protein in pathological inclusions in SALS and in the
majority of the related condition frontotemporal lobar
568 J. Kirby et al.
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degeneration with ubiquitinated inclusions (FTLD-U) has
shed light on a possible common pathway leading to neu-
rodegeneration in these conditions [34]. However, an
important question remains about how the other ALS-
associated genes, with their varying neuropathological
appearances, but clinically indistinguishable patterns of
disease, fit into this pathway. It is known that the patho-
logical inclusions in ALS cases associated with mutations
in SOD1 and FUS genes contain aggregated SOD1 and
FUS proteins, respectively, rather thanTDP-43 [35,36]. In
the case of SOD1, this may be consistent with the toxic
gain of function exhibited by the mutant protein, such
that production of misfolded, mislocalized and inactive
mutant protein exceeds the cells’ protein degradation
capacity resulting in formation of insoluble aggregates
[37]. Early cell models of ALS-related FUS mutants also
suggest a possible toxic gain of function mechanism with
increased cytoplasmic localization of the mutant protein
[3]. Similarly, evidence frommousemodels overexpressing
TDP-43 also suggests toxic cytoplasmic protein aggrega-
tion as a mechanism leading to neurodegeneration [38].
The mechanism of ANG-mediated neurodegeneration
has not yet been elucidated. However, functional data
from cell models suggest a role for haploinsufficiency.
ALS-associated ANG mutants have markedly decreased
ribonuclease activity and are unable to translocate to the
nucleus, both of which are essential to normal ANG
function [10,39]. The mutant forms of ANG also have
impaired neuroprotective ability [40], and are proposed to
act through impaired inhibition of apoptosis via the phos-
phatidylinositol 3-kinase/protein kinase B (PI3K–AKT)
signalling pathway [41], a mechanism also implicated in
SOD1-related ALS [42]. However, no functional link
between ANG and TDP-43 has yet been demonstrated,
although both are involved in distinct aspects of RNA
processing [43]. Further functional studies are required to
elucidate the pathological mechanism of ANG mutations
and their potential interaction with TDP-43.
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